Organogenesis

Organogenesis Inc. is a company based in Canton, Massachusetts, United States, specializing in the fields of biomedical engineering, manufacturing, chemical industry, tissue engineering, regenerative medicine, consumer biotechnology, medicine, technology, biology, biotechnology, healthcare, and engineering. The company was founded on January 1, 1985 and is currently active.

Organogenesis is a public company listed on the Nasdaq exchange under the stock symbol ORGO. The company has received a total funding amount of $20,000,000, with its latest funding round taking place in May 2017. Investors in Organogenesis include Eastward Capital Partners.

The company is led by CEO Gary S. Gillheeney and CFO David C. Francisco. Organogenesis has a workforce of between 500 and 999 employees.

Organogenesis has been assigned five patents and operates an official website at https://organogenesis.com. The company can also be found on social media platforms such as LinkedIn (https://www.linkedin.com/company/organogenesis) and Facebook (https://www.facebook.com/Organogenesis).